Program to Highlight UGN-102 and Company’s Innovative Early-stage Pipeline Programs Company to Report Third Quarter 2021 Financial Results on November 15, 2021 PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 1, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and
Clinically Meaningful Response and Sustained Durability Underscore Potential for UGN-102 to Become a Non-Surgical Primary Therapeutic Treatment for Patients with Highly Recurrent LG IR-NMIBC 65% Complete Response (CR) Rate at Three Months 61% of Patients Remain in CR at 12 Months Data Supports
PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 23, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the Cantor Fitzgerald 2021 Virtual
Final data from Phase 2b OPTIMA II trial of UGN-102 showed complete and durable response for intravesical instillation in patients with low-grade intermediate risk NMIBC Long-term data from pivotal OLYMPUS trial underscores durable benefit of Jelmyto ® for adult patients with low-grade upper tract
PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 10, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the H.C.
PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 3, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (“RSUs”) to
Strong Jelmyto® net product revenue of $13.0 million for the second quarter of 2021, representing more than 70% growth over the first quarter of 2021 Nearly 100 global centers activated for Phase 3 landmark ATLAS trial with lead pipeline candidate, UGN-102 Commenced Jelmyto geographic expansion
Jelmyto ® granted expedited review in Israel Jelmyto is the only US FDA approved treatment for low-grade upper tract urothelial cancer PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 28, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel
Conference Call and Webcast Scheduled for Wednesday, August 4, 2021 at 8:30 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 28, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic
73% growth in net product revenue over 1Q 2021 to approximately $13.0 million in 2Q 2021 2Q 2021 operating expenses anticipated in the range of $33 to $38 million Full 2Q 2021 financial results and conference call to be reported on Wednesday, August 4, 2021 PRINCETON, N.J. --(BUSINESS WIRE)--Jul.
